SCHEMBL847144

SCHEMBL847144

CCN(CC)CCNC(=O)/C(=C/c1ccccc1)NC(C)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
CYP2D6 P10635 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 6/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
NFKB1 P19838 1/20 0.43
KCNH2 Q12809 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 2/20 0.42
CYP3A4 P08684 1/20 0.42
THRB P10828 1/20 0.42
BLM P54132 1/20 0.42
ATM Q13315 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL847415 0.88 KMT2A (0.45) KMT2AMEN1CYP2D6SMN1; SMN2ALDH1A1
SCHEMBL847404 0.87 SMN1; SMN2 (0.57) KMT2AMEN1SMN1; SMN2ALDH1A1NPC1
SCHEMBL847490 0.84 ALDH1A1 (0.45) KMT2AMEN1CYP2D6SMN1; SMN2ALDH1A1
SCHEMBL5498513 0.81 MEN1 (0.46) KMT2AMEN1SMN1; SMN2ALDH1A1NPC1
SCHEMBL27489787 0.77 PLAAT5 (0.62) KMT2AALDH1A1NPC1KDM4EHPGD
SCHEMBL847480 0.74 MAPK1 (0.51) KMT2AMEN1SMN1; SMN2ALDH1A1NPC1
SCHEMBL22645341 0.74 ALDH1A1 (0.59) KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL7220755 0.74 ALDH1A1 (0.51) KMT2ASMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL847400 0.72 KMT2A (0.78) KMT2AMEN1SMN1; SMN2ALDH1A1HPGD
SCHEMBL786716 0.72 AKR1C3 (0.57) KMT2AMEN1ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8497397-B2 Substituted acrylamide derivative and pharmaceutical composition comprising the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-30 US disclosed
US-8497397-B2 Substituted acrylamide derivative and pharmaceutical composition comprising the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-30 US disclosed
EP-1880720-B1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAIICHI SANKYO CO LTD (JP) 2013-02-13 EP disclosed
US-20120220593-A1 Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-08-30 US disclosed
US-20120220593-A1 Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-08-30 US disclosed
US-8143446-B2 Substituted acrylamide derivative and pharmaceutical composition comprising the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-27 US disclosed
US-8143446-B2 Substituted acrylamide derivative and pharmaceutical composition comprising the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-27 US disclosed
US-20090118199-A1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAIICHI SANKYO COMPANY , LIMITED (JP) 2009-05-07 US disclosed
EP-1880720-A1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118199-A1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME ACR, NAT1, C1S KMT2A 4205/4885MEN1 691/4885CYP2D6 26/4885
US-20120220593-A1 Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same ACR, NAT1, C1S KMT2A 4205/4885MEN1 691/4885CYP2D6 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.